SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 32
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 29 30 31 32
|
presentations:
1 to
50 of
1571
|
Introduction of Speakers Part 1
Comparing Empirical HIV Incidence With UNAIDS Estimated Incidence Declines in Sub-Saharan Africa (ABSTRACT
126)
Oliver Stevens
Imperial College London, London, UK
All-Cause and Cause-Specific Mortality Trends Among Persons With and Without HIV in Rural Tanzania (ABSTRACT
128)
Julie Ambia
University of Bristol, Bristol, UK
Associations of Dolutegravir and the COVID-19 Pandemic on Viral Suppression in South African Adults (ABSTRACT
129)
Haroon Moolla
University of Cape Town, Cape Town, South Africa
Questions and Answers Part 1
Introduction of Speakers Part 2
A Multistage Sampling Approach to Refine HIV Mortality Estimates in KwaZulu-Natal, South Africa (ABSTRACT
130)
Alastair VanHeerden
Human Sciences Research Council, Pretoria, South Africa
Genotypic Characterization of Mpox and a Tale of 2 Co-Circulating Viruses in Uganda (ABSTRACT
131)
Nicholas Bbosa
London School of Hygiene & Tropical Medicine, London, UK
Characterization of Mpox Cases in Uganda: Diversity of the Confirmed Cases (ABSTRACT
132)
Ritah Namusoosa
Ministry of Health Uganda, Kampala, Uganda
Questions and Answers Part 2
Introduction of Speakers Part 1
5’Leader Defects in HIV Plasma Clones Drive 80% of Persistent Viremia on Long-Term ART (ABSTRACT
100)
Francesco R. Simonetti
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
BACH2-Driven Tissue Resident Memory Programs Promote HIV-1 Persistence (ABSTRACT
101)
Yulong Wei
Yale University, New Haven, CT, USA
Longitudinal Co-Evolution of HIV-1 Reservoir Cells and Immune Effector Cells During Long-Term Art (ABSTRACT
102)
Weiwei Sun
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
AZD5582 and Venetoclax Reduce SIV Reservoirs in ART-Suppressed Macaques (ABSTRACT
103)
Benedicth Ukhueduan
Emory University, Atlanta, GA, USA
Questions and Answers Part 1
Introduction of Speakers Part 2
HIV GAG x CD3 Soluble TCR Bispecific Reduces the Active HIV Reservoir in a Phase I/II Trial (ABSTRACT
104)
Beatriz Mothe
Fundació Lluita contra la SIDA, Badalona, Spain
Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI (ABSTRACT
105)
Thumbi Ndung'u
Africa Health Research Institute, Mtubatuba, South Africa
A Single Infusion of CCR5-/- CD4 Tscm Cells Promotes Control of SIV Upon ATI (ABSTRACT
106)
Ashish A. Sharma
Emory University, Atlanta, GA, USA
RIO: A Randomised Placebo-Controlled Study of 2 LS-bNAbs in People Treated in Early HIV (ABSTRACT
107)
Sarah Fidler
Imperial College London, London, UK
Questions and Answers Part 2
Introduction of Speakers Part 1
Maternal Tenofovir Prophylaxis With Active Immunization to Prevent Infant Hepatitis B (ABSTRACT
117)
Gonzague Jourdain
Chiang Mai University, Chiang Mai, Thailand
Efficacy of Home Visits for Pregnant Couples to Promote Couple HIV Testing and Family Health (ABSTRACT
118)
Lynae Darbes
University of Michigan, Ann Arbor, MI, USA
Dolutegravir Does Not Reduce Levonorgestrel or Medroxyprogesterone Acetate Concentrations in WLWH (ABSTRACT
119)
Rebecca Ryan
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
Lenacapavir Pharmacokinetics, Safety, and Efficacy in Adolescents and Adults in PURPOSE 1 (ABSTRACT
120)
Katherine Gill
Desmond Tutu HIV Foundation, Cape Town, South Africa
Questions and Answers Part 1
Introduction of Speakers Part 2
Assessing IIT and Mortality Among CLHIV <15 yo in PEPFAR-Supported Countries, FY21 - FY24 (ABSTRACT
121)
Michelle Yang
US Department of State, Washington, DC, USA
Multidose PK/Safety of Dolutegravir Dispersible Tablets & Oral Films in Neonates: PETITE-DTG Study (ABSTRACT
122)
Adrie Bekker
Stellenbosch University, Cape Town, South Africa
Genotypic Resistance in the African Paediatric CHAPAS-4 Trial of Second-Line Antiretroviral Therapy (ABSTRACT
123)
Alasdair Bamford
Great Ormond Street NHS Foundation Trust, London, UK
Abemaciclib, a CDK4/6 Inhibitor, in HIV-Associated and HIV-Negative Kaposi Sarcoma (ABSTRACT
124)
Jose R. Mercado-Matos
National Cancer Institute, Bethesda, MD, USA
Differences in Treatment and Overall Survival in People With and Without HIV and Oropharynx Cancer (ABSTRACT
125)
Elizabeth Chiao
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Questions and Answers Part 2
Introduction of Speakers Part 1
Trends in Hepatitis C Virus (HCV) Infection Incidence Among PWH Engaged in Care in the US: 1995-2023 (ABSTRACT
108)
Yotam Arens
Weill Cornell Medicine, New York, NY, USA
HIV Decreases Both Hepatitis B Antibody Titer and Neutralization After Spontaneous HBV Control (ABSTRACT
109)
Chloe Thio
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
HBV Care Continuum and Associated Factors in Rwanda: A Population-Based Study From 2016-2023 (ABSTRACT
110)
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
Intrahepatic Transcriptomics in HBV-HIV Co-Infection Uncover Host Responses to HBV Transcription (ABSTRACT
111)
Che-Min Lo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Questions and Answers Part 1
Introduction of Speakers Part 2
Highly Durable Seroprotection With HepB-CpG Vaccine in People With HIV (PWH): ACTG A5379 (BEeHIVe) (ABSTRACT
112)
Kristen Marks
Weill Cornell Medicine, New York, NY, USA
Epigenetic Age Predictors of Semaglutide-Related Liver Fat Changes in People With HIV (ABSTRACT
113)
Alina Pang
Weill Cornell Medicine, New York, NY, USA
Supplemental High-Dose Rifampicin and Levofloxacin for Inpatients With Disseminated HIV-TB (ABSTRACT
114)
Graeme Meintjes
University of Cape Town, Cape Town, South Africa
Casual Contact in Community Settings Explains Majority of TB Transmission in South Africa (ABSTRACT
115)
Neel R. Gandhi
Emory University, Atlanta, GA, USA
DOLPHIN-Moms: Pharmacokinetics of Dolutegravir and HIV Viral Suppression With 1HP or 3HP in Pregnancy (ABSTRACT
116)
Jyoti Mathad
Weill Cornell Medicine, New York, NY, USA
Questions and Answers Part 2
Introduction of Speakers Part 1
Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome (ABSTRACT
151)
Onyema Ogbuagu
Yale University, New Haven, CT, USA
|
<< first | < prev
page:
of 32
|
records per page:
next >
| last >>
|
| pages: 1 2 3 4 5 ... 29 30 31 32
|
presentations:
1 to
50 of
1571
|
